Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status

類似資料

• Effects of sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes
  著者:: Nunoi, Kiyohide, 等
  出版事項: (2018)
• Basal insulin secretion capacity predicts the initial response and maximum levels of beta‐hydroxybutyrate during therapy with the sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin, in relation to weight loss
  著者:: Sato, Yuichi, 等
  出版事項: (2019)
• Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline
  著者:: Tobe, Kazuyuki, 等
  出版事項: (2017)
• Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
  著者:: Matsubayashi, Yasuhiro, 等
  出版事項: (2021)
• Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
  著者:: Matsubayashi, Yasuhiro, 等
  出版事項: (2020)